for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mylan NV

MYL.O

Latest Trade

14.73USD

Change

-0.06(-0.37%)

Volume

1,097,532

Today's Range

14.62

 - 

14.89

52 Week Range

12.75

 - 

23.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.78
Open
14.75
Volume
1,097,532
3M AVG Volume
107.05
Today's High
14.89
Today's Low
14.62
52 Week High
23.11
52 Week Low
12.75
Shares Out (MIL)
516.95
Market Cap (MIL)
7,640.48
Forward P/E
3.26
Dividend (Yield %)
--

Next Event

Q3 2020 Mylan NV Earnings Release

Latest Developments

More

Australia's ACCC Says Will Not Oppose Mylan NV'S Proposed Merger With Pfizer'S Upjohn Inc Division

Mylan Says FDA Issued Warning Letter To API Manufacturer, Mylan Laboratories Limited – Unit 7

Mylan, Biocon Biologics Announce Launch Of Semglee In U.S.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mylan NV

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.

Industry

Biotechnology & Drugs

Contact Info

Unit 4, Trident Place, Mosquito Way

AL10 9UL

United Kingdom

+44.1707.853000

https://www.mylan.com

Executive Leadership

Robert J. Coury

Executive Chairman of the Board

Rajiv Malik

President, Executive Director

Heather M. Bresch

Chief Executive Officer, Executive Director

Mark W. Parrish

Lead Independent Non-Executive Vice Chairman of the Board

Robert J. Cindrich

Non-Executive Independent Director

Key Stats

2.28 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

11.9K

2018

11.4K

2019

11.5K

2020(E)

11.6K
EPS (USD)

2017

4.560

2018

4.580

2019

4.420

2020(E)

4.532
Price To Earnings (TTM)
28.23
Price To Sales (TTM)
0.66
Price To Book (MRQ)
0.65
Price To Cash Flow (TTM)
3.61
Total Debt To Equity (MRQ)
103.34
LT Debt To Equity (MRQ)
76.57
Return on Investment (TTM)
1.07
Return on Equity (TTM)
0.87

Latest News

Latest News

UPDATE 1-S.Africa's Aspen sells thrombosis drug business to Mylan, shares jump

South African drugmaker Aspen Pharmacare has agreed to sell the rights to its European thrombosis business to U.S. pharmaceutical company Mylan for almost 642 million euros ($759 million), sending its shares up 7% on Tuesday.

Mylan tightens revenue estimates on COVID-19 pressure; shares fall

Mylan NV <MYL.O> on Thursday lowered the top-end of its full-year sales estimate, saying a recovery of demand for its non-coronavirus related medicines would take until at least the end of the year, sending its shares down as much as 3.5%.

Mylan posts quarterly profit compared to year-earlier loss

Mylan NV reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.

Biogen loses bid to block Mylan sales of Tecfidera while patent fight unfolds

An appeals court on Thursday declined to temporarily block Mylan from selling a version of Tecfidera, Biogen's blockbuster multiple sclerosis drug, while an appeal in patent litigation between the two pharmaceutical companies plays out.

BRIEF-Mylan And Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval Of Hulio (Adalimumab-Fkjp)

* MYLAN AND FUJIFILM KYOWA KIRIN BIOLOGICS ANNOUNCE U.S. FDA APPROVAL OF HULIO® (ADALIMUMAB-FKJP)

BRIEF-Mylan Initiates Voluntary Nationwide Recall Of One Lot Of Daptomycin For Injection

* MYLAN INITIATES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF DAPTOMYCIN FOR INJECTION, DUE TO THE PRESENCE OF PARTICULATE

Mylan prices its generic remdesivir in India at $64 per 100 mg vial

Mylan NV said on Monday it would launch a generic version of Gilead Sciences Inc's COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

Mylan to launch generic remdesivir version in India at $64 per 100 mg vial

Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.

BRIEF-Mylan Secures Regulatory Approval For Remdesivir Lyophilized Powder For Injection 100 Mg/Vial In India

* MYLAN SECURES REGULATORY APPROVAL FOR REMDESIVIR LYOPHILIZED POWDER FOR INJECTION 100 MG/VIAL IN INDIA FOR RESTRICTED EMERGENCY USE IN COVID-19 PATIENTS

BRIEF-Mylan Shareholders Overwhelmingly Approve Proposed Combination With Upjohn

* MYLAN SHAREHOLDERS OVERWHELMINGLY APPROVE PROPOSED COMBINATION WITH UPJOHN

U.S. court rules in favor of Mylan over Biogen's key MS drug patent

A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug, Tecfidera, sending Biogen's shares down nearly 6%.

BRIEF-U.S. District Court Finds Mylan Has Convincing Evidence That Asserted Claims By Biogen For Patent Associated With Tecfidera Are Invalid

* U.S. DISTRICT COURT FINDS MYLAN HAS CONVINCING EVIDENCE THAT ASSERTED CLAIMS BY BIOGEN FOR PATENT ASSOCIATED WITH TECFIDERA ARE INVALID

U.S. district court rules for Mylan in MS drug patent battle with Biogen

A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug Tecfidera, sending the drugmaker's shares down 7%.

BRIEF-Mylan Continues To Target About $1 Billion Of Debt Repayment During 2020

* MYLAN - CONTINUES TO TARGET ABOUT $1 BILLION OF DEBT REPAYMENT DURING 2020 Source text: (https://bit.ly/3fyrqIm) Further company coverage:

BRIEF-Mylan NV Says CEO's 2019 Total Compensation Was $18.5 Mln Vs $13.3 Mln In 2018 – SEC Filing

* MYLAN NV SAYS CEO HEATHER BRESCH'S 2019 TOTAL COMPENSATION WAS $18.5 MILLION VERSUS $13.3 MILLION IN 2018 – SEC FILING

BRIEF-Mylan And Lupin Receive European Marketing Authorization For Nepexto, Biosimilar Etanercept

* MYLAN AND LUPIN RECEIVE EUROPEAN MARKETING AUTHORIZATION FOR NEPEXTO®, BIOSIMILAR ETANERCEPT Source text for Eikon: Further company coverage:

BRIEF-Lupin And Mylan Receive European Marketing Authorization For Nepexto, Biosimilar Etanercept

* LUPIN AND MYLAN RECEIVE EUROPEAN MARKETING AUTHORIZATION FOR NEPEXTO, BIOSIMILAR ETANERCEPT Source text for Eikon: Further company coverage:

BRIEF-Revance And Mylan To Advance Development Program For Biosimilar To Botox

* REVANCE AND MYLAN TO ADVANCE DEVELOPMENT PROGRAM FOR BIOSIMILAR TO BOTOX®

BRIEF-Mylan Invalidates Sanofi's Lantus Solostar Device Patents In IPR Proceedings

* MYLAN INVALIDATES SANOFI'S LANTUS® SOLOSTAR® DEVICE PATENTS IN IPR PROCEEDINGS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up